Kantar Health Blog

  • VYXEOS scores a 10 over 7+3

    by Stephanie Hawthorne | Jun 4, 2016
    Stephanie Hawthorne
    Oncology Conference Insight: ASCO 2016 --- Therapeutic approaches for acute myeloid leukemia (AML) have gone unchanged for several years. Most newly diagnosed patients achieve complete remission (CR) with a combination regimen of cytarabine plus an anthracycline (7+3 most commonly). However, the high rate of CR comes at the cost of a high level of toxicities with this regimen.
    Continue Reading > | Go comment! | Share
  • Kantar Health Spotlights Key Abstracts at ASCO 2016

    by Jay Grisolano | May 10, 2016
    Jay Grisolano
    ASCO 2016 is sure to live up to its reputation for delivering market-changing data and trends from the world of oncology. Kantar Health spotlights four potentially noteworthy abstracts that are likely to generate much discussion and significantly influence patient care.
    Continue Reading > | Go comment! | Share
  • Arnold DuBell
    Oncology Conference Insight: AACR 2016 --- Patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) have few treatment prospects and a poor prognosis. The unmet need for this indication is illustrated by the fact that only one-half of patients will receive second-line treatment, while even fewer patients will receive third-line therapy or beyond.
    Continue Reading > | Go comment! | Share
  • Arnold DuBell
    Oncology Conference Insight: ASCO GI 2016 --- It seems impossible to attend an oncology conference these days without immuno-oncology being a significant focus, and it’s starting to become passé. Well, not quite. Two years ago the idea of this treatment class playing a role in gastrointestinal (GI) cancers seemed unlikely.
    Continue Reading > | Go comment! | Share
  • Buparlisib may be a BELLE only for select patients

    by Arnold DuBell | Dec 14, 2015
    Arnold DuBell
    Oncology Conference Insight: SABCS 2015 --- In the past, patients with hormone receptor-positive (HR+), HER2-negative metastatic breast cancer were treated with single-agent hormonal agents – either tamoxifen if the patient is premenopausal or an aromatase inhibitor (AI) if she is postmenopausal.
    Continue Reading > | Go comment! | Share